OncoMatch/Clinical Trials/NCT05947487
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
Is NCT05947487 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CD70-targeting CAR-T cells for solid tumor, adult.
Treatment: CD70-targeting CAR-T cells — In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive advanced/metastatic solid tumors . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: CD70 antigen expression level ≥ 30% (≥ 30%)
CD70 antigen expression level ≥ 30%
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any systemic therapy — first-line or more
failed to at least first-line treatment or initially diagnosed advanced/metastatic solid tumors that have no NCCN guideline recommended standard first-line therapy
Cannot have received: CD70-CAR T cell therapy
Previously received CD70-CAR T cell therapy
Cannot have received: cytotoxic chemotherapy
Exception: within 4 weeks or 5 half-lives before enrollment
Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment
Cannot have received: monoclonal antibody
Exception: within 4 weeks or 5 half-lives before enrollment
Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment
Cannot have received: immunotherapy
Exception: within 4 weeks or 5 half-lives before enrollment
Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment
Lab requirements
Blood counts
anc ≥1.5x10^9/l; platelet count ≥75x10^9/l; hemoglobin ≥90 g/l
Kidney function
serum creatinine ≤1.5 x uln or creatinine clearance of ≥60 ml/min
Liver function
serum ast and serum alt ≤3.0 x uln (≤5 x uln for patients with liver cancer or metastases); total serum bilirubin ≤1.5 x uln (≤3 x uln for patients with liver cancer or metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify